Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Juvenile Idiopathic Arthritis
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 43
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Dexamethasone; Biological · Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Duarte, California • Norwalk, Connecticut • Indianapolis, Indiana + 6 more

Conditions: Healthy Adult Participants
Interventions: PF-07248144, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Induced Vaginal Delivery, Induced; Birth
Interventions: Outpatient transcervical foley balloon, Inpatient Vaginal Misoprostol; Procedure
Lead sponsor: Hurley Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Multiple Myeloma
Interventions: TBL 12; Drug
Lead sponsor: Jagannath, Sundar, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: INS018_055, Placebo; Drug
Lead sponsor: InSilico Medicine Hong Kong Limited; Industry
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: VX-814, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more

Conditions: Multiple System Atrophy, MSA
Interventions: AZD3241, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Stanford, California • New Haven, Connecticut • Tampa, Florida + 4 more

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Severe Alzheimer's Disease
Interventions: Donepezil Hydrochloride (Aricept); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Insomnia, Attention Deficit Hyperactivity Disorder
Interventions: eszopiclone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 73
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 58
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 138
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more

Conditions: Healthy
Interventions: ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Acute Uncomplicated Diverticulitis
Interventions: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, Placebo, Metronidazole, Cefuroxime; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lumbar Disc Disease, Spinal Fusion, Degenerative Disc Disease
Interventions: Propranolol Hcl 40mg Tab, Placebo oral tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Interventions: Azenosertib, Carboplatin, Pembrolizumab; Drug
Lead sponsor: Filipa Lynce, MD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Narcolepsy
Interventions: JZP-110, Placebo oral tablet; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 45
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 38 more

Conditions: HIV-1 Infection, Hepatitis
Interventions: Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Blood Pressure
Interventions: Potassium Chloride, Placebo; Dietary Supplement · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pregnancy Related, Tobacco Use Disorder
Interventions: Bupropion SR, Smoking Cessation Counseling, Placebo; Drug · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: HIV Infections
Interventions: Raltegravir (MK-0518), Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more

Search by objective public record fields.

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Outpatient Transcervical Balloon For Induction of Labor

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Potassium Intake-response Trial to Control Hypertension

Bupropion for Smoking Cessation During Pregnancy

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load